Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 4/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.44 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969725 | 1.00 | LGALS8 (0.50) | LGALS8SLC6A2LGALS9LGALS3LGALS1 | |
| SCHEMBL12917696 | 0.89 | LGALS8 (0.54) | LGALS8SLC6A2LGALS9LGALS3LGALS1 | |
| SCHEMBL970381 | 0.89 | LGALS8 (0.54) | LGALS8SLC6A2LGALS9LGALS3LGALS1 | |
| SCHEMBL8328074 | 0.89 | LGALS8 (0.54) | LGALS8SLC6A2LGALS9LGALS3LGALS1 | |
| SCHEMBL8328068 | 0.89 | LGALS8 (0.54) | LGALS8SLC6A2LGALS9LGALS3LGALS1 | |
| SCHEMBL970383 | 0.89 | LGALS8 (0.54) | LGALS8SLC6A2LGALS9LGALS3LGALS1 | |
| SCHEMBL10600547 | 0.89 | TACR2 (0.44) | LGALS8SLC6A2TACR2TSHRALDH1A1 | |
| SCHEMBL22677476 | 0.88 | LGALS8 (0.48) | LGALS8SLC6A2LGALS9LGALS3LGALS1 | |
| SCHEMBL10526425 | 0.88 | LGALS8 (0.55) | LGALS8SLC6A2LGALS9LGALS3LGALS1 | |
| SCHEMBL20741969 | 0.87 | SLC6A2 (0.56) | LGALS8SLC6A2LGALS9LGALS3LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149489-B2 | Inhibitors of glycolysis useful in the treatment of brain tumors | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2235030-B1 | COMPOUND OF THE DISACCHARIDE TYPE COMPOSITION COMPRISING AND METHOD FOR PRODUCING SUCH A COMPOUND | Université de Picardie Jules Verne (FR) | 2015-08-12 | — | — | EP | disclosed |
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-06 | — | — | US | disclosed |
| EP-2235030-A1 | COMPOUND OF THE DISACCHARIDE TYPE COMPOSITION COMPRISING AND METHOD FOR PRODUCING SUCH A COMPOUND | Université de Picardie Jules Verne (FR) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009108926-A1 | INHIBITORS OF GLYCOLYSIS USEFUL IN THE TREATMENT OF BRAIN TUMORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098400-A1 | COMPOUND OF THE DISACCHARIDE TYPE COMPOSITION COMPRISING AND METHOD FOR PRODUCING SUCH A COMPOUND | UNIVERSITE DE PICARDIE JULES VERNE (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | PDK2, G6PD, PCK2 | LGALS8 2115/4885SLC6A2 1422/4885LGALS9 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.